1)  adalimumab
adalimumab
2)  efalizumab
依法利珠单抗
3)  Natalizumab
那他珠单抗
1.
The reintroduction of Natalizumab and its risk management plan;
那他珠单抗重返市场给药品风险管理的启示
2.
Progress in treatment of natalizumab on multiple sclerosis;
那他珠单抗治疗多发性硬化研究进展
4)  Omalizumab
Omalizumab
1.
Omalizumab: A New Drug of Anti-allergic Disorder and Its Clinical Application;
抗变态反应性疾病新药Omalizumab及其临床应用
2.
Novel anti-allergy drugs targeting IgE have developed quickly, in which humanized anti-IgE monoclonal antibody Omalizumab (Xolair?) has been authorized by FDA for clinical treatment and showed prominent curative effect in adult moderate or severe asthma.
以IgE分子作为靶点获得的抗过敏药物发展较为迅速,其中,人源化抗IgE单抗Omalizumab(Xolair?)已于2003年6月获FDA批准上市,在成人中重度哮喘的临床治疗中疗效显著。
5)  omalizumab
奥马珠单抗
1.
Treatment with omalizumab for bronchial asthma;
奥马珠单抗对支气管哮喘的治疗作用
6)  Daclizumab
塞尼哌
1.
Objective: To study the effects of immunological tolerance induced by administration of allogeneic splenocytes through portal vein in rats in combination with Daclizumab.
目的:观察异基因脾细胞经门静脉途径输注诱导受体免疫耐受的效果,以及联合使用塞尼哌后的效果。
参考词条
补充资料：托曲珠利
分子式：C18H14F3N3O4S
分子量：425.38
CAS号：69004-03-1

性质：

说明：补充资料仅用于学习参考，请勿用于其它任何用途。